Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OCRELIZUMAB Cause Bone density decreased? 25 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 25 reports of Bone density decreased have been filed in association with OCRELIZUMAB (OCREVUS). This represents 0.0% of all adverse event reports for OCRELIZUMAB.

25
Reports of Bone density decreased with OCRELIZUMAB
0.0%
of all OCRELIZUMAB reports
0
Deaths
10
Hospitalizations

How Dangerous Is Bone density decreased From OCRELIZUMAB?

Of the 25 reports, 10 (40.0%) required hospitalization.

Is Bone density decreased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OCRELIZUMAB. However, 25 reports have been filed with the FAERS database.

What Other Side Effects Does OCRELIZUMAB Cause?

Covid-19 (11,454) Fatigue (5,704) Urinary tract infection (3,618) Headache (3,036) Multiple sclerosis (2,609) Asthenia (2,509) Nasopharyngitis (2,479) Gait disturbance (2,384) Pneumonia (2,333) Pain (2,327)

What Other Drugs Cause Bone density decreased?

EMTRICITABINE\TENOFOVIR DISOPROXIL (16,315) TENOFOVIR DISOPROXIL (10,586) EFAVIRENZ\EMTRICITABINE\TENOFOVIR DISOPROXIL (9,547) COBICISTAT\ELVITEGRAVIR\EMTRICITABINE\TENOFOVIR DISOPROXIL (4,529) EMTRICITABINE\RILPIVIRINE\TENOFOVIR DISOPROXIL (3,497) TERIPARATIDE (1,178) DENOSUMAB (968) METHOTREXATE (599) ADALIMUMAB (584) TOCILIZUMAB (573)

Which OCRELIZUMAB Alternatives Have Lower Bone density decreased Risk?

OCRELIZUMAB vs OCRIPLASMIN OCRELIZUMAB vs OCTINOXATE\OCTISALATE\ZINC OCRELIZUMAB vs OCTINOXATE\OCTOCRYLENE OCRELIZUMAB vs OCTREOTIDE OCRELIZUMAB vs OCTREOTIDE\OCTREOTIDE

Related Pages

OCRELIZUMAB Full Profile All Bone density decreased Reports All Drugs Causing Bone density decreased OCRELIZUMAB Demographics